AU2017254657A1 - Use of Nicotinic acid Riboside or Nicotinamide Ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors - Google Patents

Use of Nicotinic acid Riboside or Nicotinamide Ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors Download PDF

Info

Publication number
AU2017254657A1
AU2017254657A1 AU2017254657A AU2017254657A AU2017254657A1 AU 2017254657 A1 AU2017254657 A1 AU 2017254657A1 AU 2017254657 A AU2017254657 A AU 2017254657A AU 2017254657 A AU2017254657 A AU 2017254657A AU 2017254657 A1 AU2017254657 A1 AU 2017254657A1
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
derivatives
nad
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017254657A
Other languages
English (en)
Inventor
Hadi Cassier
Ryan DELLINGER
Aron Erickson
Marie E. Migaud
Mark Morris
Troy Rhonemus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromadex Inc
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of AU2017254657A1 publication Critical patent/AU2017254657A1/en
Priority to AU2022221384A priority Critical patent/AU2022221384C1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
AU2017254657A 2016-04-20 2017-04-20 Use of Nicotinic acid Riboside or Nicotinamide Ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors Abandoned AU2017254657A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022221384A AU2022221384C1 (en) 2016-04-20 2022-08-22 Use of Nicotinic acid Riboside or Nicotinamide Ribosite derivatives, and reduced derivatives thereof, as nad+ increasing precursors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325264P 2016-04-20 2016-04-20
US62/325,264 2016-04-20
PCT/US2017/028673 WO2017184885A1 (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022221384A Division AU2022221384C1 (en) 2016-04-20 2022-08-22 Use of Nicotinic acid Riboside or Nicotinamide Ribosite derivatives, and reduced derivatives thereof, as nad+ increasing precursors

Publications (1)

Publication Number Publication Date
AU2017254657A1 true AU2017254657A1 (en) 2018-11-15

Family

ID=60088650

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017254657A Abandoned AU2017254657A1 (en) 2016-04-20 2017-04-20 Use of Nicotinic acid Riboside or Nicotinamide Ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors
AU2022221384A Active AU2022221384C1 (en) 2016-04-20 2022-08-22 Use of Nicotinic acid Riboside or Nicotinamide Ribosite derivatives, and reduced derivatives thereof, as nad+ increasing precursors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022221384A Active AU2022221384C1 (en) 2016-04-20 2022-08-22 Use of Nicotinic acid Riboside or Nicotinamide Ribosite derivatives, and reduced derivatives thereof, as nad+ increasing precursors

Country Status (13)

Country Link
US (1) US10183036B2 (OSRAM)
EP (1) EP3445359B8 (OSRAM)
JP (3) JP7089480B2 (OSRAM)
KR (1) KR20190008246A (OSRAM)
CN (1) CN109640984A (OSRAM)
AU (2) AU2017254657A1 (OSRAM)
BR (1) BR112018071573A2 (OSRAM)
CA (1) CA3021571C (OSRAM)
ES (1) ES2948968T3 (OSRAM)
MX (1) MX393076B (OSRAM)
NZ (1) NZ747693A (OSRAM)
WO (1) WO2017184885A1 (OSRAM)
ZA (1) ZA201807736B (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3322419B1 (en) 2015-07-15 2025-09-03 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
PT3331894T (pt) 2015-08-05 2021-04-07 Metro Int Biotech Llc Derivados mononucleotídicos de nicotinamida e suas utilizações
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
AU2017356475B2 (en) 2016-11-11 2023-11-30 ChromaDex Inc. Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
WO2018102426A1 (en) 2016-11-29 2018-06-07 University Of Iowa Research Foundation Use of nad precursors for improving maternal health and/or offspring health
WO2018191771A1 (en) * 2017-04-18 2018-10-25 Victor Chang Cardiac Research Institute Detection and treatment of congenital malformations
SG11201912267SA (en) 2017-06-19 2020-01-30 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
AU2019214858B2 (en) * 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CA3141304A1 (en) * 2018-05-22 2019-11-28 Jumpstart Fertility Pty Ltd Amino acid salts of nicotinic acid ribosides as anti-aging agents
US11833167B2 (en) 2018-12-17 2023-12-05 Mitopower Llc Nicotinyl riboside compounds and their uses
MX2021010043A (es) * 2019-02-21 2022-07-19 Chromadex Inc Uso de nicotinamida ribósido, ácido nicotinico ribósido, compuestos de nicotinil ribósido reducido y derivados de compuestos de nicotinil ribósido en formulaciones.
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
CN113784720A (zh) * 2019-06-05 2021-12-10 雀巢产品有限公司 用于治疗/预防骨骼肌疾病的还原型烟酰胺核糖核苷
US20220323468A1 (en) * 2019-06-05 2022-10-13 Societe Des Produits Nestle S.A. Reduced nicotinamideribosides for the treatment/prevention of liver disease
EP3980026B1 (en) * 2019-06-05 2024-07-31 Société des Produits Nestlé S.A. Reduced nicotinamide ribosides for treating or preventing kidney disease
CN110973260A (zh) * 2019-12-11 2020-04-10 杨力 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用
EP4076458A1 (en) 2019-12-19 2022-10-26 Leibniz-lnstitut Für Altersforschung Nad-precursors and dietary restriction for treating age-related medical conditions
WO2021180731A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions
EP4117680A1 (en) * 2020-03-09 2023-01-18 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of lung diseases and conditions
WO2021180732A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions
WO2021180741A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions
CN114561342B (zh) * 2020-11-27 2024-12-20 西安交通大学医学院第一附属医院 Nad信号通路激动剂在体外胚胎培养中的应用
CN115669929A (zh) * 2021-01-15 2023-02-03 江苏恒正合生命科学有限公司 辅助改善记忆的功能性食品其制备方法
EP4333858A2 (en) * 2021-05-05 2024-03-13 Société des Produits Nestlé S.A. Composition and methods using combination of narh and nr to produce intracellular nicotinamide adenine dinucleotide (nad+)
CN117545488A (zh) 2021-05-27 2024-02-09 麦德龙国际生物科技有限责任公司 烟酸单核苷酸及其酯的结晶固体以及其制作和使用方法
JP2024523126A (ja) * 2021-06-18 2024-06-28 ミトパワー エルエルシー Ｎｒｈ、ｎａｒｈ、及びそれらの還元誘導体を用いた免疫関連障害、腎障害、肝障害、溶血性障害、及び酸化的ストレス関連障害の処置
JP7111878B1 (ja) 2021-10-27 2022-08-02 旭化成ファーマ株式会社 ニコチンアミドモノヌクレオチドの製造方法
EP4422644A4 (en) * 2021-10-27 2025-08-27 Elysium Health Inc METHODS OF TREATING MENOPAUSAL SYNDROMES
WO2023150072A1 (en) 2022-02-01 2023-08-10 Sinclair David A Compositions and methods for the preservation of plant matter
WO2023150667A2 (en) * 2022-02-04 2023-08-10 Elysium Health Inc. Ribose linkers and conjugates thereof
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022680B2 (en) * 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7927859B2 (en) * 2003-08-22 2011-04-19 Rice University High molar succinate yield bacteria by increasing the intracellular NADH availability
JP2007521835A (ja) 2004-02-10 2007-08-09 トラスティーズ・オブ・ダートマウス・カレッジ ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法
WO2006001982A2 (en) 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
EP3730507A1 (en) * 2005-11-18 2020-10-28 Cornell Research Foundation, Inc. Nicotinoyl riboside and nicotinamide riboside compositions for use in reducing toxicity induced by hmg-coa reductase inhibitors
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
MX385305B (es) * 2013-10-30 2025-03-18 Chromadex Inc Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel.
JP6559713B2 (ja) * 2014-06-06 2019-08-14 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ニコチンアミドリボシド類似体ならびにその医薬組成物および使用
MX390185B (es) * 2015-03-16 2025-03-20 Chromadex Inc Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso.
EP3322419B1 (en) 2015-07-15 2025-09-03 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
PT3331894T (pt) 2015-08-05 2021-04-07 Metro Int Biotech Llc Derivados mononucleotídicos de nicotinamida e suas utilizações
US10857172B2 (en) * 2016-04-14 2020-12-08 Chromadex, Inc. Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development

Also Published As

Publication number Publication date
EP3445359A1 (en) 2019-02-27
AU2022221384C1 (en) 2023-08-03
ES2948968T3 (es) 2023-09-22
US20170304338A1 (en) 2017-10-26
WO2017184885A1 (en) 2017-10-26
EP3445359A4 (en) 2019-12-25
BR112018071573A2 (pt) 2019-02-12
MX393076B (es) 2025-03-24
MX2018012849A (es) 2019-08-29
CN109640984A (zh) 2019-04-16
JP2023002685A (ja) 2023-01-10
JP2021176871A (ja) 2021-11-11
EP3445359C0 (en) 2023-06-07
AU2022221384B2 (en) 2023-03-23
KR20190008246A (ko) 2019-01-23
JP7089480B2 (ja) 2022-06-22
NZ747693A (en) 2023-07-28
CA3021571A1 (en) 2017-10-26
EP3445359B1 (en) 2023-06-07
US10183036B2 (en) 2019-01-22
AU2022221384A1 (en) 2022-09-22
JP7493007B2 (ja) 2024-05-30
JP2019514874A (ja) 2019-06-06
ZA201807736B (en) 2020-05-27
WO2017184885A8 (en) 2023-08-24
EP3445359B8 (en) 2023-09-06
CA3021571C (en) 2023-01-03

Similar Documents

Publication Publication Date Title
AU2022221384B2 (en) Use of Nicotinic acid Riboside or Nicotinamide Ribosite derivatives, and reduced derivatives thereof, as nad+ increasing precursors
US12433908B2 (en) Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development
AU2019214858B2 (en) Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US20200268778A1 (en) Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations
JP7637050B2 (ja) 少なくとも１つのグリシン又はその誘導体と、少なくとも１つのｎ－アセチルシステイン又はその誘導体と、少なくとも１つのニコチンアミドリボシド又はｎａｄ＋前駆体と、を使用する組成物及び方法
US20180258127A1 (en) B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
EP3993770A1 (en) Compositions and methods using trigonelline to produce intracellular nicotinamide adenine dinucleotide (nad+) for treating or preventing physiological disorders or states
HK40004710A (en) Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ DELLINGER, RYAN; RHONEMUS, TROY; MORRIS, MARK; ERICKSON, ARON; CASSIER, HADI AND MIGAUD, MARIE E.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted